ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: BCR-ABL TKIs (Imatinib, Dasatinib, Nilotinib, Ibrutnib, Bosutinib, Ponatinib): These are central to CML treatment and have well-documented ocular effects.